A US BUDGET IMPACT MODEL FOR SELINEXOR IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

被引：0
|
作者：
Bassali, J. [1 ]
Gould, I [2 ]
Mladsi, D. D. [2 ]
Kaye, J. A. [3 ]
Shah, J. [1 ]
Mehta, J. [4 ]
机构：
[1] Karyopharm Therapeut, Newton, MA USA
[2] RTI Hlth Solut, Res Triangle Pk, NC USA
[3] RTI Hlth Solut, Waltham, MA USA
[4] Karyopharm Therapeut, Lexington, MA USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN58
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [1] A US Budget Impact Model for Selinexor in Combination with Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Gould, Ian
    Bassali, Jan
    Mehta, Jyotsna
    Shah, Jatin
    Mladsi, Dee Dee
    BLOOD, 2019, 134
  • [2] Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)
    Chen, Christine I.
    Bahlis, Nizar J.
    Gasparetto, Cristina
    Tuchman, Sascha A.
    Lipe, Brea
    Baljevic, Muhamed
    Kotb, Rami
    Sutherland, Heather J.
    Bensinger, William I.
    Sebag, Michael
    LeBlanc, Richard
    Venner, Christopher P.
    Schiller, Gary J.
    Lentzsch, Suzanne
    Callander, Natalie S.
    Rossi, Adriana C.
    Sheehan, Heidi
    Van Domelen, Dane
    Kazuharu, Kai
    Wang, Hongwei
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    White, Darrell J.
    BLOOD, 2020, 136
  • [3] US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma
    Bassali, Jan
    Gould, Ian Gopal
    Kaye, James A.
    Mladsi, Deirdre
    Mehta, Jyotsna
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 317 - 325
  • [4] Selinexor for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Anum, Babar
    Hina, Zubair
    Mainoma, Bano
    Sana, Rafique
    Arzu, Shahid
    Maham, Babar
    Waleed, Madeeha S.
    Arslan, Inayat
    Danish, Safi
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S29 - S29
  • [5] Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    White, Darrell
    LeBlanc, Richard
    Venner, Chritopher
    Bahlis, Nizar J.
    Lentzsch, Suzanne
    Gasparetto, Cristina J.
    Chen, Christine
    Lipe, Brea
    Sutherland, Heather
    Tuchman, Sascha
    Baljevic, Muhamed
    Kotb, Rami
    Sebag, Michael
    Callander, Nancy
    Bensinger, William
    Kai, Kazuharu
    Liu, Jianjun
    Sheehan, Heidi
    Estepan, Daniel Nova
    Shah, Jatin
    Schiller, Gary J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E55 - E55
  • [6] Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)
    Badros, Ashraf Z.
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander M.
    Rapoport, Aaron P.
    Kocoglu, Mehmet H.
    Lederer, Emily
    Philip, Sunita
    Lesho, Patricia
    Johnson, Ashlee
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2016, 128 (22)
  • [7] Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
    Gasparetto, Cristina
    Lentzsch, Suzanne
    Schiller, Gary
    Callander, Natalie
    Tuchman, Sascha
    Chen, Christine
    White, Darrell
    Kotb, Rami
    Sutherland, Heather
    Sebag, Michael
    Baljevic, Muhamed
    Bensinger, William
    Leblanc, Richard
    Venner, Chris
    Bahlis, Nizar
    Rossi, Adriana
    Biran, Noa
    Sheehan, Heidi
    Saint-Martin, Jean-Richard
    Van Domelen, Dane
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael
    Lipe, Brea
    EJHAEM, 2021, 2 (01): : 56 - 65
  • [8] US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma
    Dolph, Mike
    Tremblay, Gabriel
    Leong, Hoyee
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 493 - 502
  • [9] Selinexor for the treatment of patients with relapsed or refractory multiple myeloma
    Babar, Anum
    Babar, Maham
    Zubair, Hina
    Shahid, Arzu
    Rafique, Sana
    Bano, Maimona
    Waleed, Madeeha Subhan
    Khan, Maimoona
    Inayat, Arslan
    Safi, Danish
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (03) : 535 - 546
  • [10] Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).
    Gasparetto, Cristina
    Lentzsch, Suzanne
    Schiller, Gary J.
    Callander, Natalie Scott
    Tuchman, Sascha
    Bahlis, Nizar J.
    White, Darrell
    Chen, Christine
    Baljevic, Muhamed
    Sutherland, Heather J.
    Kotb, Rami
    Sebag, Michael
    LeBlanc, Richard
    Venner, Christopher P.
    Bensinger, William
    Rossi, Adriana C.
    Sheehan, Heidi
    Arazy, Melina
    Kai, Kazuharu
    Lipe, Brea
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345